YCBD - cbdMD Inc Stock Price, Fair Value and News

1.00USD+0.08 (+8.70%)Market Closed

Market Summary

USD1.00+0.08

Market Closed

8.70%

YCBD Stock Price

View Fullscreen

YCBD RSI Chart

YCBD Valuation

Market Cap

2.8M

Price/Earnings (Trailing)

-0.14

Price/Sales (Trailing)

0.12

EV/EBITDA

-0.07

Price/Free Cashflow

-1.06

YCBD Price/Sales (Trailing)

YCBD Profitability

Operating Margin

64.95%

EBT Margin

-82.59%

Return on Equity

-283.92%

Return on Assets

-132.35%

Free Cashflow Yield

-94.54%

YCBD Fundamentals

YCBD Revenue

Revenue (TTM)

24.2M

Rev. Growth (Yr)

-13.86%

Rev. Growth (Qtr)

-6.77%

YCBD Earnings

Earnings (TTM)

-20.0M

Earnings Growth (Yr)

74.81%

Earnings Growth (Qtr)

93.72%

Breaking Down YCBD Revenue

Last 7 days

-8%

Last 30 days

19.5%

Last 90 days

16.5%

Trailing 12 Months

-86.2%

How does YCBD drawdown profile look like?

YCBD Financial Health

Current Ratio

1.23

YCBD Investor Care

Shares Dilution (1Y)

109.43%

Diluted EPS (TTM)

-14.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	30.1M	27.7M	25.1M	24.2M
2022	41.5M	39.1M	37.1M	33.5M
2021	48.6M	49.2M	47.3M	44.1M
2020	39.8M	40.8M	43.2M	45.9M
2019	14.3M	21.2M	28.1M	37.8M
2018	6.8M	8.2M	459.1K	7.4M
2017	4.0M	4.7M	5.4M	5.7M
2016	0	0	2.6M	3.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of cbdMD Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 29, 2024	raines william f iii	acquired	-	-	4,000	-
Mar 29, 2024	stephen scott g.	acquired	-	-	4,000	-
Mar 29, 2024	sellers bakari t.	acquired	-	-	4,000	-
Mar 29, 2024	swift sibyl nichole	acquired	-	-	4,000	-
Jan 11, 2024	coffman raymond scott	acquired	-	-	13,011	-
May 03, 2023	kennedy thomas ronan	bought	-10,500	2.1	-5,000	interim ceo and cfo
Feb 17, 2023	stephen scott g.	acquired	-	-	5,000	-
Feb 17, 2023	swift sibyl nichole	acquired	-	-	5,000	-
Feb 17, 2023	raines william f iii	acquired	-	-	5,000	-
Feb 17, 2023	sellers bakari t.	acquired	-	-	5,000	-

Which funds bought or sold YCBD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 28, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	1.00	68.00	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	66.00	13,564	-%
Feb 26, 2024	Virtu Financial LLC	new	-	24,000	24,000	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	unchanged	-	-	165	-%
Feb 15, 2024	Farther Finance Advisors, LLC	unchanged	-	1.00	44.00	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-62.19	-3,000	2,000	-%
Feb 14, 2024	CSS LLC/IL	unchanged	-	-37,087	52,079	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	17,907	17,907	-%
Feb 14, 2024	Penserra Capital Management LLC	unchanged	-	-	12,000	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	3.00	509	-%

Are Funds Buying or Selling YCBD?

Are funds buying YCBD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own YCBD

No. of Funds

Unveiling cbdMD Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 03, 2023	american media inc	6.5%	4,242,424	SC 13G
Jun 21, 2022	coffman raymond scott	27.8%	16,731,906	SC 13D/A
May 19, 2022	coffman raymond scott	27.8%	16,731,906	SC 13D/A
Mar 02, 2022	coffman raymond scott	27.6%	16,383,987	SC 13D/A
Dec 30, 2021	coffman raymond scott	27.6%	16,092,341	SC 13D/A
Aug 19, 2021	coffman raymond scott	27.6%	0	SC 13D/A
May 19, 2021	coffman raymond scott	27.1%	15,453,366	SC 13D/A
Mar 15, 2021	coffman raymond scott	26.8%	0	SC 13D/A
Feb 24, 2021	coffman raymond scott	24.4%	12	SC 13D/A
Mar 03, 2020	justice family office llc	5.9%	0	SC 13G/A

Recent SEC filings of cbdMD Inc

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	3	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	424B3	Prospectus Filed
Apr 02, 2024	8-K	Current Report
Mar 27, 2024	424B4	Prospectus Filed
Mar 26, 2024	EFFECT	EFFECT
Mar 19, 2024	S-1/A	Initial Public Offering

Peers (Alternatives to cbdMD Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	348.8B	85.2B	-7.62%	-10.06%	9.92	4.1	6.46%	95.94%
MRK	317.6B	60.1B	3.25%	9.20%	870.05	5.28	1.40%	-97.49%
PFE	143.5B	46.5B	-8.33%	-37.34%	-103.34	3.08	42.59%	-114.62%
AMGN	141.5B	28.2B	-2.53%	7.29%	21.07	5.02	7.09%	2.52%
GILD	83.4B	27.1B	-8.60%	-20.08%	14.73	3.08	-0.60%	23.36%
TEVA	14.8B	15.8B	-0.90%	54.57%	-25.67	0.93	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	0.13%	-17.24%	-320.54	0.87	4.58%	90.97%
ALKS	4.0B	1.7B	-12.75%	-17.88%	11.28	2.41	49.61%	324.78%
BHC	3.2B	8.8B	-7.68%	16.09%	-5.35	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-6.53%	-6.23%	14	2.99	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-10.42%	-30.36%	-3.78	1.79	24.65%	80.36%
TXMD	21.8M	1.3M	-17.83%	-48.08%	-2.12	16.74	-98.14%	-109.18%
ACRX	17.1M	-	-12.17%	23.93%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-33.93%	-94.71%	-0.18	0.13	80.00%	43.08%
ACOR	422.3K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

cbdMD Inc News

Latest updates

cbdMD Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-6.8%	5,375,630	5,765,701	6,462,965	6,584,666	6,240,526	8,448,497	8,868,093	9,948,858	9,856,767	10,390,168	11,352,585	12,457,386	13,131,946	12,247,100	10,809,387	9,703,800	10,412,491	9,908,777	9,734,459	7,752,478	683,730
Cost Of Revenue	-15.9%	1,817,907	2,161,900	2,273,839	2,224,512	2,517,452	2,891,067	2,660,185	3,186,564	4,328,310	4,050,710	3,370,952	3,643,127	3,430,274	5,334,090	3,748,024	2,732,076	3,700,537	4,127,400	2,929,160	1,914,716	165,492
Gross Profit	0.2%	3,557,498	3,548,845	3,845,541	4,015,508	3,567,766	4,968,556	5,932,708	6,442,322	4,993,512	5,742,617	7,189,571	8,155,484	8,898,028	6,365,827	6,888,521	6,666,960	6,447,699	5,416,736	5,075,989	3,721,862	300,196
Operating Expenses	-	-	-	-	-	-	-	-	11,452,700	11,955,284	12,755,319	13,865,191	12,323,207	10,657,973	10,896,900	8,226,029	12,267,637	12,560,297	10,627,860	11,542,628	5,749,463	1,391,812
EBITDA Margin	10.0%	-0.81	-0.90	-0.76	-1.69	-1.62	-1.86	-1.47	-0.58	-0.74	-0.49	-0.52	-0.74	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.8%	-418	53,654	-1,246	-1,946	29,119	23,117	-1,551	-2,086	-3,234	-5,358	-2,582	-10,603	-10,386	-12,617	3,436	35,607	7,267	24,882	6,229	6,274	37,686
Income Taxes	-	-	-	-	-	-	-	-	-	-	-462,000	103,000	-536,000	332,000	1,345,300	-	-	-2,240,300	-63,000	-1,088,000	-1,075,000	-133,000
Earnings Before Taxes	93.7%	-996,501	-15,874,940	-1,770,404	-1,336,802	-3,956,062	-14,630,917	-31,634,143	-4,657,215	-19,160,904	-3,156,081	1,640,288	-13,046,474	-9,727,621	-5,363,561	-8,944,921	14,883,772	10,730,665	14,249,202	-28,021,178	-32,925,877	-1,053,931
EBT Margin	9.8%	-0.83	-0.92	-0.78	-1.71	-1.64	-1.89	-1.50	-0.61	-0.77	-0.51	-0.54	-0.76	-	-	-	-	-	-	-	-	-
Net Income	93.7%	-996,501	-15,874,941	-1,770,404	-1,336,802	-3,956,062	-14,631,432	-31,634,143	-4,657,216	-19,160,904	-3,026,082	1,537,288	-12,510,474	-9,395,621	-6,258,562	-8,952,702	14,883,772	12,929,763	11,884,544	-29,202,956	-31,850,274	-2,188,864
Net Income Margin	9.8%	-0.83	-0.92	-0.78	-1.71	-1.64	-1.89	-1.50	-0.61	-0.75	-0.49	-0.54	-0.76	-	-	-	-	-	-	-	-	-
Free Cashflow	24.3%	-290,515	-383,681	-342,962	-1,631,230	-2,241,727	-2,152,140	-2,459,358	-5,344,827	-5,699,505	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-6.8%	15,095	16,195	32,970	33,684	35,727	40,792	57,138	92,988	99,327	124,883	115,522	121,058	124,079	110,843	111,311	112,583	101,797	94,518	100,909	94,835	96,437
Current Assets	-8.7%	7,366	8,070	10,091	10,146	11,529	16,012	19,858	24,327	29,679	36,502	29,983	34,746	37,375	23,712	24,112	24,885	14,874	15,743	22,186	14,144	15,732
Cash Equivalents	-16.3%	1,505	1,798	2,847	1,719	3,353	6,720	9,554	13,337	19,697	26,411	18,984	23,712	28,764	14,825	15,006	14,836	3,661	4,690	11,633	4,640	8,032
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,116	2,065	1,192
Net PPE	10.3%	790	717	700	798	901	823	775	2,335	2,504	2,562	2,775	2,977	3,084	3,183	3,068	3,224	2,158	1,716	1,017	817	662
Goodwill	-	-	-	-	-	-	-	11,996	42,773	56,671	56,671	54,670	54,670	54,670	54,670	54,670	54,670	54,670	54,670	55,134	55,144	55,259
Liabilities	12.5%	8,058	7,164	7,238	7,898	9,136	9,367	10,538	12,965	14,927	21,741	26,242	35,173	38,359	31,661	27,731	20,426	46,272	56,914	75,763	108,251	4,600
Current Liabilities	27.9%	5,972	4,670	4,384	4,679	5,552	5,286	5,725	5,785	6,761	6,917	6,750	6,864	6,737	7,689	4,386	5,792	5,481	3,710	2,330	1,871	1,772
Long Term Debt	-100.0%	-	9*	819*	-	-	125	128	78.00	93.00	109	124	-	-	264	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	9*	819*	-	-	125	128	78.00	93.00	109	124	-	-	264	-	-	-	-	-	-	-
Shareholder's Equity	-22.1%	7,037	9,031	25,732	25,786	26,591	31,424	46,600	80,023	84,400	103,142	89,280	85,885	85,720	79,182	83,580	92,158	55,524	37,604	25,146	-	18,125
Retained Earnings	-1.1%	-176,360	-174,363	-157,488	-154,717	-152,380	-147,423	-131,791	-99,156	-93,499	-73,337	-68,977	-69,954	-56,884	-47,388	-41,029	-31,977	-46,760	-59,610	-70,782	-43,083	-11,291
Additional Paid-In Capital	0.0%	183,390	183,387	183,212	180,497	178,905	178,842	178,327	179,116	177,836	176,417	158,198	155,780	142,549	126,518	124,558	124,083	102,257	97,187	96,130	28,383	28,074
Shares Outstanding	0.0%	2,961	2,961	2,855	1,457	1,341	1,348	1,316	1,313	1,285	1,284	1,259	1,173	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-229	1,274	1,333
Float	-	-	-	-	12,718	-	-	-	42,426	-	-	-	-	-	-	-	30,947	-	-	-	42,357	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	59.8%	-105	-263	-240	-1,733	-2,064	-1,925	-2,370	-5,202	-5,468	-4,334	-4,608	-2,958	-2,192	-387	-1,130	-4,273	-4,873	-6,322	-4,592	-3,299	-1,162
Share Based Compensation	-	-	-	-	-	-	-	-	292	505	491	356	203	249	509	419	430	543	436	1,860	19.00	144
Cashflow From Investing	-53.6%	-184	-120	-102	1,102	-177	96.00	-410	-142	-231	-2,030	455	-1,423	447	282	-55.40	-1,240	-555	-527	-246	-92.48	-1,267
Cashflow From Financing	99.6%	-2.50	-665	1,471	-1,002	-1,125	-1,003	-1,001	-1,015	-1,015	13,792	-574	-669	15,685	-76.07	1,356	16,689	4,401	-93.95	11,833	-	6,179
Dividend Payments	-	-	-	-	-	-	-	-	1,001	1,001	1,334	560	560	100	100	100	100	67.00	-	-	-	-

YCBD Income Statement

2023-12-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Gross Sales	$ 5,375,630	$ 6,240,526
Allowances	(225)	(155,308)
Total Net Sales	5,375,405	6,085,218
Cost of sales	1,817,907	2,517,452
Gross Profit	3,557,498	3,567,766
Operating expenses	4,623,333	7,613,947
Loss from operations	(1,065,835)	(4,046,181)
Decrease of contingent liability	69,752	61,000
Interest expense (income)	(418)	29,119
Loss before provision for income taxes	(996,501)	(3,956,062)
Benefit for income taxes	0	0
Net Loss	(996,501)	(3,956,062)
Preferred dividends	1,000,501	1,000,502
Net Loss attributable to cbdMD, Inc. common shareholders	$ (1,997,002)	$ (4,956,564)
Net Loss per share:
Basic and Diluted earnings per share (in dollars per share)	$ (0.67)	$ (3.7)
Weighted average number of shares Basic and Diluted: (in shares)	2,960,945	1,341,277

YCBD Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 1,504,844	$ 1,797,860
Accounts receivable	1,102,180	1,216,090
Inventory	3,554,395	4,052,972
Inventory prepaid	188,250	182,675
Prepaid sponsorship	29,473	70,061
Prepaid expenses and other current assets	986,821	750,383
Total current assets	7,365,963	8,070,041
Other assets:
Property and equipment, net	790,349	716,579
Operating lease assets	3,060,405	3,350,865
Deposits for facilities	132,203	138,708
Intangible assets	3,046,248	3,219,090
Investment in other securities, noncurrent	700,000	700,000
Total other assets	7,729,205	8,125,242
Total assets	15,095,168	16,195,283
Current liabilities:
Accounts payable	1,566,633	1,906,319
Accrued expenses	3,102,468	1,484,441
Operating leases – current portion	1,302,663	1,277,089
Note payable	0	2,492
Total current liabilities	5,971,764	4,670,341
Long term liabilities:
Long term liabilities	0	9
Operating leases - long term portion	2,066,050	2,403,286
Contingent liability	20,611	90,363
Total long term liabilities	2,086,661	2,493,658
Total liabilities	8,058,425	7,163,999
Commitments and Contingencies (Note 11)
cbdMD, Inc. shareholders' equity:
Preferred stock, authorized 50,000,000 shares, $0.001 par value, 5,000,000 and 5,000,000 shares issued and outstanding, respectively	5,000	5,000
Common stock, authorized 150,000,000 shares, $0.001 par value, 2,961,056 and 1,960,573 shares issued and outstanding, respectively	2,961	2,961
Additional paid in capital	183,389,556	183,387,095
Accumulated deficit	(176,360,774)	(174,363,772)
Total cbdMD, Inc. shareholders' equity	7,036,743	9,031,284
Total liabilities and shareholders' equity	$ 15,095,168	$ 16,195,283

About cbdMD Inc

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. It distributes its products through its e-commerce website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.

CEO	Mr. T. Ronan Kennedy
WEBSITE	cbdmd.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	90

cbdMD Inc Frequently Asked Questions

What is the ticker symbol for cbdMD Inc? What does YCBD stand for in stocks?

YCBD is the stock ticker symbol of cbdMD Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of cbdMD Inc (YCBD)?

As of Wed Apr 17 2024, market cap of cbdMD Inc is 2.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of YCBD stock?

You can check YCBD's fair value in chart for subscribers.

What is the fair value of YCBD stock?

You can check YCBD's fair value in chart for subscribers. The fair value of cbdMD Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of cbdMD Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for YCBD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is cbdMD Inc a good stock to buy?

The fair value guage provides a quick view whether YCBD is over valued or under valued. Whether cbdMD Inc is cheap or expensive depends on the assumptions which impact cbdMD Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for YCBD.

What is cbdMD Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, YCBD's PE ratio (Price to Earnings) is -0.14 and Price to Sales (PS) ratio is 0.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. YCBD PE ratio will change depending on the future growth rate expectations of investors.